The Therapeutic Goods
Administration has issued
updated safety information on
the risk of bleeding associated
with Pradaxa (dabigatran).
Two safety reviews of the
medication have now been
completed, both of which have
reinforced the importance of
appropriate patient selection
for its safe use - in particular an
assessment of the risk factors for
bleeding.
There’s also a contraindication
for concomitant use of
dronedarone and dabigatran,
advice that dabigatran may have
an effect on some pathology
tests, and updated details of
adverse events.
See www.tga.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 27 May 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 May 13
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.